Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Dapagliflozin in Heart Failure
NCT06915870Completed
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in heart failure (HF) and type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Empagliflozin (2 arms). Primary endpoint: Assessment of Ejection Fraction at 12 weeks. Started Jul 2024; status: completed.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06915870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06915870.